


12-14-06

Express Mail Label No.: EV 869861390 US
Date of Deposit: December 12, 2006

Attorney Docket No.: 26505-514 NATL



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Farmer et al.
SERIAL NUMBER : 10/590,782 EXAMINER : Not Yet Assigned
INTERNATIONAL FILING DATE : February 25, 2005 ART UNIT : Not Yet Assigned
FOR : MACROCYCLIC COMPOUNDS AND METHODS OF
MAKING AND USING THE SAME

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant hereby makes of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A41 and U.S. Published Applications A42-A57 are not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: **Farmer et al.**
U.S.S.N.: **10/590,782**

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 26505-514 NATL.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Heidi A. Erlacher, Reg. No. 45,409
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: December 12, 2006

TRA 2229069v.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Farmer et al.
SERIAL NUMBER : 10/590,782 EXAMINER : Not Yet Assigned
INTERNATIONAL FILING DATE : February 25, 2005 ART UNIT : Not Yet Assigned
FOR : MACROCYCLIC COMPOUNDS AND METHODS OF
MAKING AND USING THE SAME

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (6 pages), in duplicate;
3. Copies of Cited References: B1-B76; C1-C27; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.


The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 26505-514 NATL. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Ivor R. Elrifi".

Ivor R. Elrifi, Reg. No. 39,529
Heidi A. Erlacher, Reg. No. 45,409
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: December 12, 2006



Express Mail No.: EV 869861390 US
Date of Deposit: December 12, 2006

Page 1 of 6
Attorney Docket No.: 26505-514 NATL

Please type a plus sign (+) in this box .

+

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|--|---------------------------|--------------------------|
| Modified Form 1449/PTO | | Application Number | 10/590,782 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | International Filing Date | February 25, 2005 |
| | | First Named Inventor | Farmer |
| | | Group Art Unit | Not Yet Assigned |
| | | Examiner Name | Not Yet Assigned |
| | | Attorney Docket Number | 26505-514 NATL (RIB-514) |
| | | | |

U.S. PATENT DOCUMENTS

| Exam Initials | Cite No. | U.S. Patent Document No. | Issue Date | Name of Patentee(s) or Applicant(s) | Class | Sub Class | Filing Date If Appropriate |
|---------------|----------|--------------------------|------------|-------------------------------------|-------|-----------|----------------------------|
| | *A1 | 3,629,232 | 12/21/71 | Peter Hadley Jones | 260 | 210 | |
| | *A2 | 3,681,325 | 08/01/72 | Leslie Alan Freiberg | 260 | 210 | |
| | *A3 | 4,404,201 | 09/13/83 | Haskell et al. | 424 | 246 | |
| | *A4 | 4,546,176 | 10/08/85 | Machida et al. | 544 | 21 | |
| | *A5 | 5,180,719 | 01/19/93 | White et al. | 514 | 192 | |
| | *A6 | 5,215,980 | 06/01/93 | Jones | 514 | 183 | |
| | *A7 | 5,232,918 | 08/03/93 | Arnould et al. | 514 | 202 | |
| | *A8 | 5,281,703 | 01/25/94 | White et al. | 540 | 302 | |
| | *A9 | 5,336,768 | 08/09/94 | Albrecht et al. | 540 | 222 | |
| | *A10 | 5,444,051 | 08/22/95 | Agouridas et al. | 514 | 29 | |
| | *A11 | 5,527,780 | 06/18/96 | Agouridas et al. | 514 | 29 | |
| | *A12 | 5,543,400 | 06/08/96 | Agouridas et al. | 514 | 29 | |
| | *A13 | 5,658,888 | 08/19/97 | Koga et al. | 514 | 29 | |
| | *A14 | 5,693,791 | 12/02/97 | Truett | 540 | 222 | |
| | *A15 | 5,747,467 | 05/05/98 | Agouridas et al. | 514 | 29 | |
| | *A16 | 5,780,605 | 07/14/98 | Or et al. | 536 | 7.2 | |
| | *A17 | 5,866,549 | 02/02/99 | Or et al. | 514 | 29 | |
| | *A18 | 5,891,643 | 04/06/99 | Fesik et al. | 435 | 7.1 | |
| | *A19 | 5,905,144 | 05/18/99 | Truett | 536 | 22.1 | |
| | *A20 | 5,955,440 | 09/21/99 | Sauer et al. | 514 | 29 | |
| | *A21 | 6,020,521 | 02/01/00 | Randolph et al. | 560 | 205 | |
| | *A22 | 6,034,069 | 03/07/00 | Or et al. | 514 | 29 | |
| | *A23 | 6,274,715 B1 | 08/14/01 | Or et al. | 536 | 7.4 | |
| | *A24 | 6,288,055 B1 | 09/11/01 | Natarajan et al. | 514 | 210.2 | |

Express Mail No.: EV 869861390 US
Date of Deposit: December 12, 2006

Page 2 of 6
Attorney Docket No.: 26505-514 NATL

| | | | | | | | |
|--|------|--------------|----------|------------------|-----|-----|--|
| | *A25 | 6,288,234 B1 | 09/11/01 | Griffin | 546 | 190 | |
| | *A26 | 6,355,805 B1 | 03/12/02 | Choi et al. | 546 | 301 | |
| | *A27 | 6,355,810 B1 | 03/12/02 | Griffin et al. | 548 | 574 | |
| | *A28 | 6,362,371 B1 | 03/26/02 | Moran et al. | 564 | 365 | |
| | *A29 | 6,395,724 B1 | 05/28/02 | Judice et al. | 514 | 183 | |
| | *A30 | 6,420,354 B1 | 07/16/02 | Marquess et al. | 514 | 183 | |
| | *A31 | 6,437,119 B1 | 08/20/02 | Truett | 540 | 215 | |
| | *A32 | 6,446,032 B1 | 09/03/02 | Schimmel | 703 | 11 | |
| | *A33 | 6,468,979 B1 | 10/22/02 | Pellacini et al. | 514 | 29 | |
| | *A34 | 6,479,498 B1 | 11/12/02 | Marquess et al. | 514 | 256 | |
| | *A35 | 6,566,509 B1 | 05/20/03 | Griffin et al. | 536 | 7.4 | |
| | *A36 | 6,576,615 B2 | 06/10/03 | Phan et al. | 514 | 30 | |
| | *A37 | 6,664,240 B2 | 12/16/03 | Phan et al. | 514 | 30 | |
| | *A38 | 6,710,034 B2 | 03/23/04 | Phan et al. | 514 | 30 | |
| | *A39 | 6,753,415 B2 | 06/22/04 | Phan et al. | 536 | 7.1 | |
| | *A40 | 6,878,691 B2 | 04/12/05 | Or et al. | 514 | 29 | |
| | *A41 | 7,129,221 B2 | 10/31/06 | Or et al. | 514 | 28 | |

U.S. PUBLISHED APPLICATION DOCUMENTS

| Exam Initials | Cite No. | U.S. Published Application No. | Published Date | Name of Patentee(s) or Applicant(s) | Class | Sub Class | Filing Date If Appropriate |
|---------------|----------|--------------------------------|----------------|-------------------------------------|-------|-----------|----------------------------|
| | *A42 | 2002/0028943 A1 | 03/07/02 | Griffin | 546 | 223 | |
| | *A43 | 2003/0092639 A1 | 05/15/03 | Phan et al. | 514 | 28 | |
| | *A44 | 2003/0096764 A1 | 05/22/03 | Phan et al. | 514 | 28 | |
| | *A45 | 2003/0158093 A1 | 08/21/03 | Sun et al. | 514 | 8 | |
| | *A46 | 2003/0176670 A1 | 09/18/03 | Griffin et al. | 536 | 7.4 | |
| | *A47 | 2003/0176848 A1 | 09/18/03 | Gibson et al. | 604 | 500 | |
| | *A48 | 2003/0181399 A1 | 09/25/03 | Wong et al. | 514 | 35 | |
| | *A49 | 2003/0203858 A1 | 10/30/03 | Phan et al. | 514 | 28 | |
| | *A50 | 2003/0212010 A1 | 11/13/03 | Phan et al. | 514 | 28 | |
| | *A51 | 2004/0014685 A1 | 01/22/04 | Mercep et al. | 514 | 26 | |
| | *A52 | 2004/0077612 A1 | 04/22/04 | Mercep et al. | 514 | 175 | |
| | *A53 | 2004/0097434 A1 | 05/20/04 | Mercep et al. | 514 | 28 | |
| | *A54 | 2004/0157787 A1 | 08/12/04 | Or et al. | 514 | 28 | |
| | *A55 | 2004/0235760 A1 | 11/25/04 | Phan et al. | 514 | 28 | |
| | *A56 | 2005/0020823 A1 | 01/27/05 | Phan et al. | 536 | 7.1 | |
| | *A57 | 2005/0197334 A1 | 09/08/05 | Wang et al. | 514 | 227.5 | |
| | | | | | | | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|----------|---------------------------------------|---|---------------------|--------------------|
| Exam Initials | Cite No. | Foreign Patent Document Office Number | Name of Patentee(s) or Applicant(s) | Date of Publication | Translation Yes No |
| | B1 | DE 196 04 223 A1 | BAYER AG | 08/07/97 | No |
| | B2 | DE 100 34 627 A1 | BAYER AG | 01/31/02 | No |
| | B3 | EP 0 213 617 B1 | KITASATO KENKYUSHO | 03/11/87 | |
| | B4 | EP 0 215 355 B1 | KITASATO KENKYUSHO | 03/25/87 | |
| | B5 | EP 0 643 068 B1 | CHUGAL SEIYAKU KABUSHIKI KAISHA | 03/15/95 | |
| | B6 | EP 0 680 967 B1 | HOECHST MARION ROUSSEL | 11/08/95 | Claims only |
| | B7 | EP 0 895 999 A1 | PFIZER PRODUCTS INC. | 02/10/99 | |
| | B8 | EP 1 132 392 A1 | PFIZER PRODUCTS INC. | 09/12/01 | |
| | B9 | EP 1 201 649 A1 | PFIZER PRODUCTS INC. | 05/02/02 | |
| | B10 | EP 1 201 655 A2 | PFIZER PRODUCTS INC. | 05/02/02 | |
| | B11 | WO 92/17184 | SPECIAL ADVANCED BIOMATERIALS, INC. | 10/15/92 | |
| | B12 | WO 93/07154 | PROCTER & GAMBLE PHARMACEUTICALS, INC. | 04/15/93 | |
| | B13 | WO 93/24509 | CHUGAI SEIYAKU KABUSHIKI KAISHA | 12/09/93 | Abstract only |
| | B14 | WO 94/10185 | CHUGAI SEIYAKU KABUSHIKI KAISHA | 05/11/94 | Abstract only |
| | B15 | WO 95/07271 | THE UPJOHN COMPANY | 03/16/95 | |
| | B16 | WO 96/18633 | ZAMBON GROUP S.P.A. | 06/20/96 | |
| | B17 | WO 97/35195 | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 09/25/97 | |
| | B18 | WO 97/48713 | ABBOTT LABORATORIES | 12/24/97 | |
| | B19 | WO 98/56800 | PFIZER PRODUCTS INC. | 12/17/98 | |
| | B20 | WO 98/56801 | PFIZER PRODUCTS INC. | 12/17/98 | |
| | B21 | WO 99/16779 | ABBOTT LABORATORIES | 04/08/99 | |
| | B22 | WO 99/22722 | ABBOTT LABORATORIES | 05/14/99 | |
| | B23 | WO 99/28308 | TRUETT, WILLIAM | 06/10/99 | |
| | B24 | WO 99/33839 | CHEIL JEDANG CORPORATION | 07/08/99 | |
| | B25 | WO 99/63937 A3 | ADVANCED MEDICINE, INC. | 12/16/99 | |
| | B26 | WO 99/64032 | ADVANCED MEDICINE, INC. | 12/16/99 | |
| | B27 | WO 99/64049 A1 | ADVANCED MEDICINE, INC. | 12/16/99 | |
| | B28 | WO 99/64416 | ZENECA LIMITED | 12/16/99 | |
| | B29 | WO 99/64417 | ZENECA LIMITED | 12/16/99 | |
| | B30 | WO 00/06606 | ZAMBON GROUP S.P.A. | 02/10/00 | |
| | B31 | WO 00/21960 | ZENECA LIMITED | 04/20/00 | |
| | B32 | WO 00/40589 | PLIVA, FARMACEUTSKA INDUSTRIJA | 07/13/00 | |
| | B33 | WO 00/42055 | ZAMBON GROUP S.P.A. | 07/20/00 | |
| | B34 | WO 00/77016 A1 | PLIVA D.D. | 12/21/00 | |

| | | | | | | | |
|--|-----|----|----------------|---|----------|--|--|
| | B35 | WO | 01/40222 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 06/07/01 | | |
| | B36 | WO | 01/40236 A2 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 06/07/01 | | |
| | B37 | WO | 01/40238 A1 | ENICHEM S.P.A. | 06/07/01 | | |
| | B38 | WO | 01/42242 A1 | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 06/14/01 | | |
| | B39 | WO | 01/58885 A1 | PHARMACIA & UPJOHN COMPANY | 08/16/01 | | |
| | B40 | WO | 01/80863 A1 | THE SCRIPPS RESEARCH INSTITUTE | 11/01/01 | | |
| | B41 | WO | 01/81350 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 11/01/01 | | |
| | B42 | WO | 02/051855 A2 | KOSAN BIOSCIENCES, INC. | 07/04/02 | | |
| | B43 | WO | 02/060912 A1 | ENANTA PHARMACEUTICALS, INC. | 08/08/02 | | |
| | B44 | WO | 02/080841 A2 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 10/17/02 | | |
| | B45 | WO | 02/081468 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 10/17/02 | | |
| | B46 | WO | 02/081469 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 10/17/02 | | |
| | B47 | WO | 02/081470 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 10/17/02 | | |
| | B48 | WO | 02/096890 A2 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 12/05/02 | | |
| | B49 | WO | 02/096916 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 12/05/02 | | |
| | B50 | WO | 03/022824 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 03/20/03 | | |
| | B51 | WO | 03/035073 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 05/01/03 | | |
| | B52 | WO | 03/035648 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 05/01/03 | | |
| | B53 | WO | 03/042228 A1 | GLAXO GROUP LIMITED; PLIVA D.D. | 05/22/03 | | |
| | B54 | WO | 03/070173 A2 | SYMPORE GMBH | 08/28/03 | | |
| | B55 | WO | 03/070174 A2 | SYMPORE GMBH | 08/28/03 | | |
| | B56 | WO | 03/070254 A1 | SYMPORE GMBH | 08/28/03 | | |
| | B57 | WO | 03/072575 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 09/04/03 | | |
| | B58 | WO | 2004/005309 A2 | PLIVA D.D. | 01/15/04 | | |
| | B59 | WO | 2004/005310 A2 | PLIVA D.D. | 01/15/04 | | |
| | B60 | WO | 2004/005313 A2 | PLIVA D.D. | 01/15/04 | | |
| | B61 | WO | 2004/013153 A2 | ZAMBON GROUP S.P.A. | 02/12/04 | | |
| | B62 | WO | 2004/043984 A1 | PLIVA D.D. | 05/27/04 | | |
| | B63 | WO | 2004/048392 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 06/10/04 | | |
| | B64 | WO | 2004/056817 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 07/08/04 | | |

| | | | | | | | |
|--|-----|----|----------------|---|----------|--|--|
| | B65 | WO | 2004/056818 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 07/08/04 | | |
| | B66 | WO | 2004/056819 A1 | ASTRAZENECA AB; ASTRAZENECA UK LIMITED | 07/08/04 | | |
| | B67 | WO | 2004/078770 A1 | RIB-X PHARMACEUTICALS, INC. | 09/16/04 | | |
| | B68 | WO | 2004/080391 A2 | OPTIMER PHARMACEUTICALS, INC. | 09/23/04 | | |
| | B69 | WO | 2004/094449 A1 | PLIVA PHARMACEUTICAL INDUSTRY, INC. | 11/04/04 | | |
| | B70 | WO | 2004/096221 A1 | MORPHOCHEM AKTIENGESELLSCHAFT FÜR KOMBINATORISCHE CHEMIE | 11/11/04 | | |
| | B71 | WO | 2004/108745 A2 | ENANTA PHARMACEUTICALS, INC. | 12/16/04 | | |
| | B72 | WO | 2004/108746 A2 | ENANTA PHARMACEUTICALS, INC. | 12/16/04 | | |
| | B73 | WO | 2005/042554 A1 | RIB-X PHARMACEUTICALS, INC. | 05/12/05 | | |
| | B74 | WO | 2005/049632 A1 | RIB-X PHARMACEUTICALS, INC. | 06/02/05 | | |
| | B75 | WO | 2005/075494 A1 | ZAMBON GROUP S.P.A. | 08/18/05 | | |
| | B76 | WO | 2005/085266 A2 | RIB-X PHARMACEUTICALS, INC. | 09/15/05 | | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | |
|---|----------|--|
| Exam Initials | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
| | C1 | Akritopoulou-Zanze et al., "Synthesis and antibacterial activity of novel bifunctional macrolides", <i>Bioorg. Med. Chem. Lett.</i> , pgs. 1-5 (2005) |
| | C2 | Brandt-Rauf et al., "Fluorescent assay for estimating the binding of erythromycin derivatives to ribosomes", <i>Antimicrob. Agents Chemother.</i> , 14(1):88-94 (1978) |
| | C3 | Costa et al., "Hybrids of macrolides and nucleobases or nucleosides", <i>Tetrahedron Lett.</i> , 41:3371-3375 (2000) |
| | C4 | Denis et al., "Novel N-demethylation of ketolide: application to the solution phase parallel synthesis of N-desosaminyl-substituted ketolides using ion exchange resins", <i>Tetrahedron Lett.</i> , 43:4171-4174 (2002) |
| | C5 | Faghih et al., "Synthesis of 9-deoxo-4"-deoxy-6,9-epoxyerythromycin derivatives: novel and acid-stable motilides", <i>J. Med. Chem.</i> , 41(18):3402-3408 (1998) |
| | C6 | Gregory et al., "Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The "B" group", <i>J. Med. Chem.</i> , 32(8):1673-1681 (1989) |
| | C7 | Hecker et al., "Application of hygromycin a structure activity relationships to the antibiotic a201a", <i>Bioorg. Med. Chem. Lett.</i> , 3(2):295-298 (1993) |
| | C8 | Henessian et al., "Quantamycin: a computer-simulated new-generation inhibitor of bacterial ribosomal binding", <i>J. Am. Chem. Soc.</i> , 106:6114-6115 (1984) |
| | C9 | Holmes et al., "Novel dimeric penicillin derived inhibitors of HIV-1 proteinase: interaction with the catalytic aspartates", <i>Bioorg. Med. Chem. Lett.</i> , 3(4):503-508 (1993) |
| | C10 | Hwang et al., "1,3-dipolar cycloaddition of nitrile oxides to 1-phenylsulfonyl-1,3-butadienes:synthesis of 3-(4,5-dihydroisoxazol-5-yl)pyrroles", <i>Tetrahedron Lett.</i> , 43:53-56 (2002) |
| | C11 | Jones et al., "Chemical modifications of erythromycin antibiotics. I. 3'-De(dimethylamino)erythromycin A and B", <i>Chem. Modif. Erythromycin Antibiotics</i> , 33(2):665-670 (1968) |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | |
|---|----------|---|
| Exam Initials | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
| | C12 | Liang et al., "Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics", <i>Bioorg. Med. Chem. Lett.</i> , 15:1307-1310 (2005) |
| | C13 | Mereu et al., "Design, synthesis and in vivo activity of 9-(S)-dihydroerythromycin derivatives as potent anti-inflammatory agents", <i>Bioorg. Med. Chem. Lett.</i> , 16:5801-5804 (2006) |
| | C14 | Mutak et al., "Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues", <i>J. Med. Chem.</i> , 47(2):411-431 (2004) |
| | C15 | Phan et al., "Synthesis and antibacterial activity of a novel class of 4'-substituted 16-membered ring macrolides derived from tylosin", <i>J. Med. Chem.</i> , 47(12):2965-2968 (2004) |
| | C16 | Phillips et al., "Synthesis and antibacterial activity of 5-substituted oxazolidinones", <i>Bioorg. Med. Chem.</i> , 11:35-41 (2003) |
| | C17 | Randolph et al., "Elimination of antibacterial activities of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A", <i>Bioorg. Med. Chem. Lett.</i> , 14:1599-1602 (2004) |
| | C18 | Rao et al., "Tight binding of a dimeric derivative of vancomycin with dimeric L-Lys-D-Ala-D-Ala" <i>J. Am. Chem. Soc.</i> , 119(43):10286-10290 (1997) |
| | C19 | SciFinder Database entry for WO 93/24509, pgs.1-3 (2003) |
| | C20 | SciFinder Database entry for WO 94/10185, pgs.1-3 (2003) |
| | C21 | Shuker et al., "Discovering high-affinity ligands for proteins: SAR by NMR", <i>Science</i> , 274:1531-1543 (2003) |
| | C22 | Stenmark et al., "Biomimetic synthesis of macrolide/ketolide metabolites through a selective n-Demethylation reaction", <i>J. Org. Chem.</i> , 65(12):3875-3876 (2000) |
| | C23 | Vince et al., "Chloramphenicol binding site with analogues of chloramphenicol and puromycin", <i>Antimicrob. Agents Chemother.</i> , 8(4):439-443 (1975) |
| | C24 | Wang et al., "Dimeric aminoglycosides: design, synthesis and RNA binding", <i>Bioorg. Med. Chem. Lett.</i> , 7(14):1951-1956 (1997) |
| | C25 | Welch et al., "An inhibitor of ribosomal peptidyl transferase using transition-state analogy", <i>Biochem.</i> , 34(2):385-390 (1995) |
| | C26 | Žemlička et al., "Sparsophenicol: a new synthetic hybrid antibiotic inhibiting ribosomal peptide synthesis", <i>J. Med. Chem.</i> , 25(10):1123-1125 (1982) |
| | C27 | Žemlička et al., "Hybrid of antibiotics inhibiting protein synthesis. Synthesis and biological activity", <i>J. Med. Chem.</i> , 36(9):1239-1244 (1993) |

* By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A41 and of the U.S. Published Applications A42-A57 are not submitted.

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.